Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and have a major place in the treatment of atherosclerotic disease. Recent studies have shown anti-infl ammatory properties of statins. The purpose of this study was to evaluate the anti-infl ammatory eff ect of simvastatin on bleomycin (BLM)-induced pulmonary fi brosis in rats. A total of 31 female Sprague-Dawley rats were divided into four groups: (1) intratracheal (IT) phosphate-buff ered saline (PBS) + intraperitoneal (IP) PBS (n=7); (2) IT BLM + IP PBS (n=8); (3) IT BLM + low dose (LD) simvastatin (1 mg/kg daily, n=8); (4) IT BLM + high dose (HD) simvastatin (5 mg/kg daily, n=8). Simvastatin was administered IP for 15 days, beginning 1 day prior to IT BLM. The eff ect of simvastatin on pulmonary fi brosis was studied by measurements of IL-13, PDGF, IFN-γ, TGF-β1 levels in bronchoalveolar lavage (BAL) fl uid and lung tissue hydroxyproline (HPL) content and by histopathological examination (Ashcroft score). BLM caused signifi cant change in BAL fl uid cytokine levels and increased both HPL content and histopathological score (p<0.001 for all). While LD simvastatin had no eff ect on cytokine levels, HD signifi cantly reduced IL-13 (15.12 ±7.08 pg/ml vs. 4.43±2.34 pg/mL; p<0.05) and TGF-β1 levels (269.25 ±65.42 pg/mL vs. 131.75±32.65 pg/mL; p<0.05). Neither HD nor LD simvastatin attenuated HPL content or Ashcroft score. In conclusion, this study showed that LD simvastatin had no eff ect on a BLMinduced pulmonary fi brosis model, while the high dose caused partial improvement in profi brotic cytokine levels.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown origin. Its incidence is estimated to be 20 per 10,000 for males and 13 per 100,000 for females. The survival rate varies from 2 to 4 years (Kim et al., 2006) . Patients with IPF are usually treated with corticosteroids and/or cytotoxic agents such as azathioprine or cyclophosphamide; the poor effi ciency and significant side effects of these medications create, however, an urgent need for novel drugs with better effi cacy and tolerance.
Statins are widely prescribed drugs with a positive eff ect on morbidity and mortality in cardiovascular disease. In recent years several studies have shown these positive eff ects of statins to be due both to their lipid lowering and antiinfl ammatory eff ect (Albert et al., 2001; Nissen et al., 2005; Ridker et al., 1998) . Positive results in experimental trials have been obtained through the anti-infl ammatory effi cacy of statins in numerous respiratory disease models such as asthma, smoking-induced emphysema, pulmonary hypertension, IPF, acute lung injury and lung transplantation (Hothersall et al., 2006) . Bleomycin (BLM)-induced pulmonary fi brosis is the most common pulmonary experimental model in rodents (Chua et al., 2005) . This model produces pathological fi ndings similar to those in human pulmonary fi brosis; it is widely used in the assessment of potential antifi brotic drugs. A search of published literature shows that rodents used in studies carried out with BLM-induced pulmonary fi brosis model are male.
There is, on the other hand, a generally shared expectation that female animals may enhance fi brosis by increasing both infl ammatory and immune responses through the estrogen hormones or a modifi ed cytokine expression, although several studies indicate the opposite (Gharaee-Kermani et al., 2005; Voltz et al., 2008) .
The aim of this study was to investigate the antiinfl ammatory and antifi brotic effi ciency of simvastatin, the eff ectiveness of which was already shown in the BLM-induced pulmonary fi brosis model in doses approaching those used in humans.
METHODS

Animals
The study was approved by Selcuk University Experimental Medical Research and Application Center Experimental Animal Ethics Committee. Thirty-one female Sprague Dawley rats weighing 200-230g were studied. The animals were maintained in a controlled environment and fed on rodent chow and tap water ad libitum, in 12-hour light, 12-hour dark cycles. They were free of respiratory and other diseases.
Preparation of simvastatin
Simvastatin (Merck, Sharp & Dohme, Middlesex, U.K.) was prepared as a 4 mg/mL stock solution. Briefl y, 4 mg of simvastatin were dissolved in 100 μL of ethanol and 150 μL of 0.1 N NaOH and incubated at 50 °C for 2 h, then the pH was adjusted to 7 and the total volume corrected to 1 mL. The stock solution was diluted to the appropriate concentration in sterile phosphate-buff ered saline (PBS) immediately before use (McKay et al., 2004) .
Experimental Model and Experimental Groups
All animals were anesthetized with a mixture of xylazine (10 mg/kg, Rompun; Bayer AG, Leverkusen, Germany) and ketamine (70 mg/kg, Ketalar®; Parke Davis, Eczacibasi, Istanbul, Turkey) administered by intramuscular (IM) injection before the surgical procedures. The trachea was exposed after a small cervical skin incision and separation of strap muscles, and punctured with a 26-gauge needle for the administration of bleomycin sulphate (BLM; Bleocin-S, Nippon Kayaku Co., Ltd, Tokyo, Japan) (Borzone et al., 2001) . A single dose of 2.5 U/kg BLM dissolved in 0.3 mL PBS was instilled by intratracheal (IT) injection. This dose of BLM was selected from previous experiments to cause consistent biochemical and histological damage without mortality (Serrano-Mollar et al., 2002) . Control animals received 0.3 mL PBS IT.
Simvastatin solution was administered intraperitoneally (IP) in two diff erent doses, low dose (LD, 1 mg/kg) or high dose (HD, 5 mg/kg) beginning 1 day before the start of BLM application. Control animals received PBS. The animals were randomly distributed into four weight-matched study groups: (1) IT PBS + IP PBS (n = 7); (2) IT BLM + IP PBS (n = 8); (3) IT BLM + IP LD simvastatin (n = 8); (4) IT BLM + IP HD simvastatin (n = 8).
The rats were sacrifi ced by transsection of the abdominal aorta while under an overdose of pentobarbital (80 mg/kg IP) 14 days after IT bleomycin or saline instillation.
Bronchoalveolar lavage fl uid
After clamping the right main bronchus, bronchoalveolar lavage (BAL) fl uid was obtained from the left lung. Lavage was performed four times with 3 mL NaCl 0.9%. Samples were stored in the refrigerator at -80 °C until analysis. Levels of interleukin (IL)-13, interferon (IFN)-γ, platelet derived growth factor (PDGF)-A and transforming growth factor (TGF)-β were performed with the ELISA technique using commercially available kits. The Invitrogen Rat IL-13 (BioSource, Invitrogen, USA,Cat #KRC0132/KRC0131), Invitrogen Multispecies TGF-β (BioSource, Invitrogen, USA,Cat #KAC1688/KAC1688), Rat IFN-γ (BenderMedSystems, Austria, Cat #BMS621) and Quantikine Mouse/Rat PDGF-AB (R&D Systems, USA, Cat #MHD00) kits were used for determination of these parameters in BAL fl uid.
Measurement of hydroxyproline concentration in the lung
The left lung was ligated and cut at the hilum, freed of extraneous tissue, blotted on fi lter paper and snap frozen in liquid nitrogen. The tissues were stored in Eppendorf tubes at -80 °C until the time of biochemical analysis. Frozen tissue samples were weighed before analysis and subjected to alkaline hydrolysis. Briefl y, the tissue samples were placed in Eppendorf tubes with 1 mL of 2 N NaOH; the tubes were sealed with rubber stoppers and incubated for one hour in an autoclave at 120 °C. Derivatization followed hydrolysis and 50 μL of the sample was injected into an HPLC system (Shimadzu Prominence /Japan). A commercially available HPLC hydroxyproline (HPL) analysis kit (Eureka, Italy) was used for this analysis with a UV/VIS detector at 495 nm. Lung tissue hydroxyproline contents were reported as mg/g frozen tissue.
Histological studies of the lungs
Histopathological evaluation was carried out on the right lungs that were not lavaged. The right lung was fi xed by IT infusion of formalin under 25 cm hydrostatic pressure. Lung tissue was embedded in paraffi n and sections stained with hematoxylineosin for examination by light microscopy. Ashcroft's scoring system (Ashcroft et al., 1988) was used to estimate the severity of pulmonary fi brosis on a numerical scale in a blind evaluation by the same pathologist (HT) ( Table 1) .
Stasistical Analysis
We performed power analysis to determine the sample size. Eff ect size was based on results of the study of Ou et al. (2008) , and sample size was set to 7 per group for a power of 80% 
RESULTS
Eff ect of simvastatin on IL-13, PDGF, IFN-γ and TGF-β1 levels
BAL fl uid recovery rate, ranging from 84 to 90%, was not signifi cantly diff erent among the four groups. IT instillation of BLM caused signifi cant increases in IL-13, PDGF, and TGF-β1 and a signifi cant decrease in IFN-γ levels. HD simvastatin significantly decreased the levels of IL-13 and TGF-β1 (p<0.001). There was, however, no signifi cant change in the PDGF or IFN-γ levels. LD simvastatin administration did not correlate with any signifi cant change in IL-13, PDGF, IFN-γ or TGF-β1 levels. Details are shown in Table 2 .
Eff ect of simvastatin on HPL content
IT BLM caused a significant increase in lung HPL concentration, which is a marker of collagen deposition, on day 14 (p<0.001). Neither LD nor HD administration of simvastatin with IT BLM caused a signifi cant decrease in HPL content (Table 3) .
Histopathological assessment
Haematoxylin-eosin stained lung sections were examined by light microscopy on Day 14. The lungs of the control group animals showed normal, free alveoli and interalveolar spaces (Fig 1a) . Those of animals given BLM presented infl ammatory infi ltration, alveolar wall thickening and increase in interstitial collagen deposition (Fig. 1b) . The animals who had received pre-treatment with simvastatin before BLM showed moderate edema and infl ammation of perialveolar tissues with increased fi brotic changes (Fig. 1c) .
In the assessment of lung sections according to Ashcroft's scoring system, the BLM-PBS group had the highest Ashcroftfi brosis score. Either LD or HD simvastatin before IT BLM did not result in signifi cant decrease in histopathological scores (Table 3) .
DISCUSSION
In this study of the eff ect of simvastatin on BLM-induced pulmonary fi brosis in rats, we could not determine a positive eff ect of either a high (5 mg/kg) or a low (1 mg/kg) dose of simvastatin on fi brosis formation. Only the levels of IL-13 and TGF-β1 were found to be lower in the sim vastatin group than in the BLM group, at the dose of 5 mg/kg.
TABLE 2
Bronchoalveolar lavage (BAL) fl uid levels of IL-13, PDGF-A, IFN-γ and TGF-β1 in control rats, rats given bleomycin only, and rats given either low-dose or high-dose simvastatin The anti-infl ammatory eff ect of the statins is independent of their lipid reducing eff ect; diff erent statins have diff erent actions on infl ammatory cells (Nagashima et al., 2006) . Kiener et al. (2001) demonstrated that atorvastatin and simvastatin, the lipophilic statins, have a substantially greater antiinfl ammatory eff ect than hydrophilic pravastatin. It is therefore important to realize that all the statins cannot have the same potential. Some statins may even show eff ects opposite to those of others. For example, in a study with 27 healthy volunteers comparing the 14-day effects of simvastatin, 40 mg and atorvastatin, 20 mg, simvastatin led to an increase in HLA-DR and MHC38 in T-cell expression, while the latter appeared to downregulate the same markers (Fehr et al., 2004) . In addition, superantigen-mediated T-cell activation was inhibited by simvastatin, while atorvastatin, conversely, sensitized these cells. Simvastatin has been shown to be effective on the profi brogenic mechanisms in IPF and signifi cantly inhibited the CTGF gene and protein expression, overriding induction by TGF β-1, a known potent inducer of CTGF (Watts et al., 2005) . Several experimental trials showed an eff ect of simvastatin and pravastatin on BLM induced pulmonary fi brosis (Kim et al., 2010; Ou et al., 2008) .
Experimental data suggest that the anti-inflammatory and antifi brotic eff ects of simvastatin could be utilized in clinical practice for pulmonary disease such as asthma and IPF. However, the positive experimental results could not be demonstrated in clinical trials. For example, in a study by Menzies et al. (2007) of the anti-infl ammatory eff ect of simvastatin in asthma patients, simvastatin was not correlated with any signifi cant changes in the infl ammatory markers, lung volume or airway resistance. A retrospective review by Nadrous et al. (2004) of the contribution of ACE inhibitors and statins on IPF survival indicated that statins did not contribute to survival. Also, numerous case reports related to statin use in recent years have raised questions about the positive eff ects of statins in pulmonary fi brosis (Fernandez et al., 2008) .
The effect of simvastatin on BLM-induced pulmonary fi brosis was previously discussed in one report only. In this study, Ou et al. (2008) evaluated the eff ect of simvastatin on histopathological scores, lung HPL content, inflammatory response, fibrogenic cytokines and profibrogenic markers. Administration of simvastatin for 28 days doses of 5 and 20 mg/kg showed statistically signifi cant changes in all the parameters. The comparison of the antifi brotic activity of the high and low dose groups indicated a signifi cant diff erence in favor of the high-dose group. In our study, on the other hand, simvastatin was administered at lower doses and for a shorter time; no signifi cant change was seen in the pulmonary fi brosis markers.
New drugs are usually tested for safety and effi cacy in animal models before being used in clinical trials. It is well known that discrepancies exist between animal and human data and that a drug that is active in the animal may be useless in the human (Perel et al., 2007) . Such an occurrence is often due to inappropriate translation of the drug dose from one animal species to another. Dose calculation based on body surface area (BSA) is accepted as the most appropriate method for translating doses among species (Reagan-Shaw et al., 2008) . A BSA-based translation of the doses used in our study would result in doses of approximately 12 mg and 60 mg daily doses for a human weighing 60 kg. The dose range for simvastatin in human use is 20-80 mg/day for cardiovascular disease; statinrelated side eff ects such as myopathy are known to be dosagedependent (Escobar et al., 2008) . Furthermore, in experimental studies high doses of simvastatin are reported to increase the risk of toxicity and mortality (Palmer et al., 2004) . In the study by Palmer et al. (2004) of statin eff ect in collagen-induced arthritis, the anti-infl ammatory activity of simvastatin was seen only after administration of 40 mg/kg; serious side eff ects were observed during treatment. Only 7 of 18 mice completed therapy.
Ou et al. (2008) sacrifi ced the rats after 28 days of IT BLM administration, while histological evaluation was performed after 14 days in our study. The time point of 14 days was considered as the most suitable for a comparative study in a BLM-induced PF model, as fi brosis is reported to decrease after 14 days (Izbicki et al., 2002) . Also, in a study evaluating the immune modulating eff ects of statins (Fehr et al., 2004) , a 14-day statin administration was shown to be suffi cient for the immune system eff ects to occur. The selected 14-day evaluation period in our study appears to be optimal for judging both the simvastatin eff ect and the fi brosing eff ect of BLM.
TGF-β1, PDGF-A, IL-13 and IFN-γ are biochemical endpoints used in many fibrosis evaluations (Scotton and Chambers, 2007) . We found an increase of TGF-β1, PDGF-A and IL-13 levels, and a decrease in the IFN-γ level, in line with the published literature. However, a signifi cant decrease of IL-13 and TGF-β1, compared to the BLM group, was only observed in the HD simvastatin group. TGF-β is one of the principal mediators in the pathophysiology of pulmonary
TABLE 3
Hydroxyproline (HPL) contents and grade of pulmonary fi brosis in control rats, rats given bleomycin only, and rats given either low dose or high-dose simvastatin fi brosis. This cytokine aff ects extracellular matrix remodeling through multiple processes and is essential for several types of experimental fi brosis (Branton and Kopp, 1999) . Therefore, inhibition of TGF-β signaling was intensively studied to evaluate the effi ciency of antifi brotic therapies. Positive eff ects on fi brosis of therapies targeting TGF-β pathways were found (Bonniaud et al., 2005; de Gouville and Huet, 2006) . Another profi brotic cytokine, IL-13, is a T-helper type 2 cytokine; it can stimulate the production of fi broblast collagen independently from TGF-β (Kolodsick et al., 2004) . The important role of IL-13 in pulmonary fi brosis was clearly shown both in in vivo and in vitro studies (Gharaee-Kermani et al., 2001; Zhu et al., 1999) . Jakubzick et al. (2003) assessed the effi ciency of a chimeric IL-13 immunotoxin (IL-13-PE) in BLM-challenged mice. This study showed that IL-13-binding cells are essential for BLM-induced PF and the importance of antifibrotic therapies targeting IL-13 in pulmonary fi brosis. Examining experimentally the eff ects of simvastatin on allergic airway reaction and airway reactivity, Zeki et al. (2009) showed that simvastatin decreases airway infl ammation, inhibits T-cell type 1 and 2, and improves lung physiology in the asthmatic mouse model. Simvastatin was administered in a much higher dose (40 mg/kg) than in our study; the IL-13 level in the lung lavage fl uid decreased signifi cantly. Most experimental PF studies hitherto reported have been carried out in male rats, since the female gender is defi ned as a crucial factor for the development and prognosis of IPF. However, there are controversial indications from studies, suggesting that both the male and the female gender play a negative role in pulmonary fi brosis. Gharaee-Kermani et al. (2005) investigated the effects of gender and estradiol on pulmonary fi brosis in female and male rats in the BLMinduced pulmonary fi brosis model. They found more frequent and severe fi brotic lesions in the female rats. In this study, BLM was administered at a dose of 7.5 U/kg; all the male rats survived, while a high mortality rate of 80±5% was calculated for the female animals. Whereas Voltz et al. (2008) , reported that androgens, too, play a worsening role in the BLM-induced pulmonary fibrosis model. However, invasive pulmonary function tests were used in this study and no significant difference could be shown between animals of either sex in terms of the results of frequently used biochemical and histological indices of pulmonary fi brosis. Opposite results have, however, been reported in some clinical studies. In humans, even though the IPF incidence is higher in men, the incidence of the familial form of IPF is higher in women, who also have a comparatively poorer prognosis (Barzo, 1985; Wockel and Sultz, 1995) . Several studies have, to the contrary, reported a poorer the prognosis in men with IPF compared to women (Gribbin et al., 2006; Olson et al., 2007) . In our study, histologically confi rmed fi brosis was achieved in female rats with 2.5 U/kg BLM, without mortality. This fi nding is one of the important results of the study.
Groups
In conclusion, simvastatin could not be shown to exert a favorable eff ect on BLM-induced PF in our study in female rats. Partial favorable eff ects in biochemical targets, in the group given HD treatment, suggest that favorable results could be possible at such high doses when interpreted in combination with results from the other studies. However, considering the relationship between high-dose administration and the risk of toxicity, we believe that further studies should be conducted on this subject.
